Anesthesia for Cesarean Section in Dogs

Both alfaxalone and propofol are safe and effective induction agents for canine cesarean section when anesthesia is maintained with isoflurane in oxygen, and puppy survival does not differ between them. The measurable difference is early neonatal vigor: in a randomized trial of 22 bitches and 81 puppies delivered by emergency cesarean section, induction with alfaxalone 1–2 mg/kg IV to effect produced higher modified Apgar scores than propofol 2–6 mg/kg IV to effect at 5, 15, and 60 minutes after delivery, an overall estimated score difference of 3.3 points on a 10-point scale (95% CI, 1.6–4.9; P < 0.001). The proportion of puppies surviving to 3 months was similar between groups. In a separate multicentre randomized trial of 74 bitches, no puppy variable differed significantly between induction agents: 24-hour puppy survival was 96% (205/213 puppies) after alfaxalone induction and 95% (124/131) after propofol induction, with no bitch fatalities in the study.

Study details

Doebeli et al. (Theriogenology, 2013): 22 bitches undergoing emergency cesarean section (81 puppies), randomly allocated to induction agent after assessment that surgery was indicated.

• Induction: alfaxalone 1–2 mg/kg or propofol 2–6 mg/kg body weight, administered intravenously to effect to allow endotracheal intubation.
• Maintenance: isoflurane in oxygen.
• Neonatal vitality assessed with a modified Apgar score (heart rate, respiratory effort, reflex irritability, motility, mucous membrane color; maximum score = 10) at 5, 15, and 60 minutes after delivery.
• Apgar scores were higher in the alfaxalone group at 5, 15, and 60 minutes; overall estimated score difference 3.3 (95% CI, 1.6–4.9; P < 0.001). Induction drug and time of scoring were associated with the Apgar score; delivery time was not.
• Neither the number of puppies delivered nor the proportion of puppies surviving up to 3 months after delivery differed between groups.
• Conclusion: both agents can be safely used for induction for emergency cesarean section; puppy survival was similar, but alfaxalone was associated with better neonatal vitality during the first 60 minutes after delivery.

Metcalfe et al. (Australian Veterinary Journal, 2014): multicentre, randomized, positive-controlled clinical trial of 74 bitches, 48 (65%) induced with alfaxalone and 26 (35%) with propofol.

• Induction doses: not stated in the abstract; the doses on this page come from the Doebeli trial only.
• Maintenance: isoflurane and oxygen, with bitches receiving a number of concurrent medications throughout the peri-operative period (not named in the abstract).
• Quality scores: induction rated excellent in 47/48 (98%) alfaxalone bitches versus 23/26 (88%) propofol bitches; anesthesia effectiveness rated excellent in 39/48 (81%) versus 17/26 (65%).
• Recovery scores did not differ between groups, with good or excellent recovery in 46/48 (96%) alfaxalone and 25/26 (96%) propofol bitches. No bitch fatalities occurred.
• Puppy viability (suction, dorsal flexion, withdrawal and anogenital reflexes) showed no statistically significant differences between groups; 24-hour survival of live-born puppies was 205/213 (96%) with alfaxalone versus 124/131 (95%) with propofol.
• Conclusion: alfaxalone is safe and effective for induction of anesthesia prior to cesarean section, with a negligible effect on the neonate.

Clinical context and limitations

Both trials induced with the study agent and maintained with isoflurane in oxygen, so the evidence speaks to induction agent choice under that maintenance protocol. The neonatal-vigor finding (higher Apgar scores with alfaxalone) comes from one trial of 22 bitches presenting for emergency cesarean section; the larger multicentre trial found no significant difference in reflex-based puppy viability measures, so the two trials should not be merged into a single claim. Neither abstract addresses premedication, analgesia planning (systemic opioids, epidural, incisional blocks), neonatal resuscitation specifics, or bitches with dystocia-related comorbidities such as hypovolemia or exhaustion, and the Metcalfe trial’s group sizes (48 alfaxalone vs 26 propofol) reflect an allocation the abstract does not explain.

Ask Vetinuity

For follow-up questions about the induction doses, the Apgar and viability findings, or what this evidence covers for bitches with dystocia-related comorbidities, ask the Vetinuity clinical assistant.